• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

勘误：JAK抑制剂在非感染性炎症性眼病中的疗效与安全性：一项来自国际AIDA网络注册库的前瞻性队列研究

Corrigendum: Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries.

作者信息

Vitale Antonio, Palacios-Olid Judith, Caggiano Valeria, Ragab Gaafar, Hernández-Rodríguez José, Pelegrín Laura, Mejía-Salgado Germán, Zarate-Pinzón Laura, Gentileschi Stefano, Sota Jurgen, Fonollosa Alex, Carreño Ester, Gaggiano Carla, Amin Rana Hussein, Balistreri Alberto, Narváez Javier, Tosi Gian Marco, Frediani Bruno, Cantarini Luca, de-la-Torre Alejandra, Fabiani Claudia

机构信息

Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, University of Siena, Siena, Italy.

Azienda Ospedaliero-Universitaria Senese [European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], Siena, Italy.

出版信息

Front Med (Lausanne). 2024 Sep 13;11:1489092. doi: 10.3389/fmed.2024.1489092. eCollection 2024.

DOI:10.3389/fmed.2024.1489092
PMID:39346944
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11427952/
Abstract

[This corrects the article DOI: 10.3389/fmed.2024.1439338.].

摘要

[本文更正了文章的数字对象标识符：10.3389/fmed.2024.1439338。]

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6126/11427952/1b96c729dbef/fmed-11-1489092-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6126/11427952/1b96c729dbef/fmed-11-1489092-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6126/11427952/1b96c729dbef/fmed-11-1489092-g0001.jpg

相似文献

1
Corrigendum: Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries.勘误：JAK抑制剂在非感染性炎症性眼病中的疗效与安全性：一项来自国际AIDA网络注册库的前瞻性队列研究
Front Med (Lausanne). 2024 Sep 13;11:1489092. doi: 10.3389/fmed.2024.1489092. eCollection 2024.
2
Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries.Janus激酶抑制剂在非感染性炎症性眼病中的疗效与安全性：一项来自国际AIDA网络注册库的前瞻性队列研究。
Front Med (Lausanne). 2024 Aug 23;11:1439338. doi: 10.3389/fmed.2024.1439338. eCollection 2024.
3
Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib.所有的 JAK 抑制剂在治疗类风湿关节炎方面都等效吗？托法替布、巴瑞替尼、乌帕替尼和费乐替尼疗效的调整间接比较。
Clin Rheumatol. 2023 Dec;42(12):3225-3235. doi: 10.1007/s10067-023-06787-2. Epub 2023 Oct 13.
4
Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.三种获批用于治疗类风湿关节炎的 Janus 激酶抑制剂（托法替布、巴瑞替尼和乌帕替尼）的药代动力学药物相互作用潜力的关键性评估。
Drug Saf. 2020 Aug;43(8):711-725. doi: 10.1007/s40264-020-00938-z.
5
Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis.在初治的类风湿关节炎患者中，与甲氨蝶呤相比，托法替布、巴瑞替尼、乌帕替尼和菲诺替尼的缓解率和低疾病活动率相对较高。
Pharmacology. 2023;108(6):589-598. doi: 10.1159/000527186. Epub 2023 Aug 17.
6
Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.托法替布、巴瑞替尼和乌帕替尼治疗类风湿关节炎的疗效和安全性：系统评价和荟萃分析。
Mayo Clin Proc. 2020 Jul;95(7):1404-1419. doi: 10.1016/j.mayocp.2020.01.039. Epub 2020 Jun 1.
7
Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.酪氨酸激酶2抑制剂德卡伐替尼与Janus激酶1/2/3抑制剂相比的选择性概况
Dermatol Ther (Heidelb). 2021 Oct;11(5):1763-1776. doi: 10.1007/s13555-021-00596-8. Epub 2021 Aug 30.
8
Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.托法替布、巴瑞替尼、乌帕替尼、费卢替尼和培非替尼单药治疗活动性类风湿关节炎的疗效和安全性比较。
J Clin Pharm Ther. 2020 Aug;45(4):674-681. doi: 10.1111/jcpt.13142. Epub 2020 Jun 3.
9
Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration.向美国食品药品监督管理局报告的Xeljanz/Xeljanz XR、Olumiant和Rinvoq不良事件的特征。
J Manag Care Spec Pharm. 2022 Sep;28(9):1046-1052. doi: 10.18553/jmcp.2022.28.9.1046.
10
Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.比较托法替布、巴瑞替尼、乌帕替尼和氟可替尼与甲氨蝶呤在类风湿关节炎初治患者中的疗效和安全性。
Z Rheumatol. 2021 Nov;80(9):889-898. doi: 10.1007/s00393-020-00889-x. Epub 2020 Sep 24.